Modulation of Lipoprotein B Binding to the LDL Receptor by Exogenous Lipids and Apolipoproteins CI, CII, CIII, and E
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
We have recently shown that apo B–containing lipoproteins isolated by immunoaffinity chromatography bind to the LDL receptor with an affinity dependent on their apo E or apo CIII content. However, these lipoproteins—LpB:E, LpB:CIII, and LpB:CIII:E—isolated from whole plasma have variable lipid and apolipoprotein contents, and it is difficult to consider each parameter separately, particularly because an increase in the apo CIII content is always associated with an increase in the content of other C apolipoproteins. Therefore, we used affinity-purified LpB free of other apolipoproteins. Lipid content of LpB was increased by incubation with a lipid emulsion, and this triglyceride-enriched LpB was named TG-LpB. Free apo CI, apo CII, apo CIII, and apo E were added to LpB and TG-LpB and their associations to the lipoprotein were assessed by gel filtration, nondenaturing electrophoresis, and immunoblotting. Molar ratios of 6 (apo E), 30 (apo CII), 20 (apo CIII), and 30 (apo CI) for 1 apo B were obtained. The association of apo CII to LpB and TG-LpB induced modifications to the LpB structure and a redistribution of lipids and apolipoproteins on the lipoprotein particles. The binding of these LpBs and TG-LpBs with and without added apo CI, CII, CIII, and E was tested at 4°C on the LDL receptors of HeLa cells. The increased content of lipids reduced TG-LpB binding to the LDL receptor. Addition of apo CIII to LpB decreased its affinity, although this decrease was lower than that observed with LpB:CIII prepared from whole plasma. Apo CIII almost completely abolished the interaction of TG-LpB with the receptor, indicating a synergistic effect of lipids and apo CIII. The apo CIII effect was specific and cannot be obtained with apo CI. With apo CII, an inhibitory effect can also be obtained but to a lesser extent than with apo CIII. At 37°C the C apolipoproteins decreased the catabolism of LpB and TG-LpB by the LDL receptor of fibroblasts. Addition of apo E to either LpB or TG-LpB had a small effect on the binding of the enriched lipoproteins at 4°C but markedly increased their catabolism at 37°C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424
Cited by
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3
Jong, M. C., Hofker, M. H., & Havekes, L. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.472 · Cited by 539
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association
Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V., Gonzalez-Campoy, J. M., Jones, S. R., Kumar, R., La Forge, R., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.04.001 · Cited by 521
Fruchart, J.-C., Duriez, P., & Staels, B. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199906000-00007 · Cited by 425
Self-citationInvolvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies
Chew, H., Solomon, V. A., & Fonteh, A. N. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00598 · Cited by 353
Schissel, S. L., Jiang, X.-C., Tweedie-Hardman, J., Jeong, T.-S., Camejo, E. H., Najib, J., Rapp, J. H., Williams, K. J., & Tabas, I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.5.2738 · Cited by 322
Kawakami, A., Aikawa, M., Alcaide, P., Luscinskas, F. W., Libby, P., & Sacks, F. M. (2006) · Circulation · doi:10.1161/circulationaha.106.622514 · Cited by 305
Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism
Shachter, N. S. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200106000-00009 · Cited by 288
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
Claudel, T., Inoue, Y., Barbier, O., Duran-Sandoval, D., Kosykh, V., Fruchart, J., Fruchart, J.-C., Gonzalez, F. J., & Staels, B. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00896-5 · Cited by 268
Self-citationKawakami, A., Aikawa, M., Libby, P., Alcaide, P., Luscinskas, F. W., & Sacks, F. M. (2006) · Circulation · doi:10.1161/circulationaha.105.591743 · Cited by 206
Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032056 · Cited by 170
Schwartz, E. A., Koska, J., Mullin, M. P., Syoufi, I., Schwenke, D. C., & Reaven, P. D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.028 · Cited by 173
Cohn, J. S., Marcoux, C., & Davignon, J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.10.2474 · Cited by 156
Mendivil, C. O., Zheng, C., Furtado, J., Lel, J., & Sacks, F. M. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.197830 · Cited by 145
Vu-Dac, N., Gervois, P., Torra, I. P., Fruchart, J. C., Kosykh, V, Kooistra, T., Princen, H. M., Dallongeville, J., & Staels, B. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1581 · Cited by 143
Self-citationA review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease
Kei, A. A., Filippatos, T. D., Tsimihodimos, V., & Elisaf, M. S. (2012) · Metabolism · doi:10.1016/j.metabol.2011.12.002 · Cited by 136
Onat, A., Hergenç, G., Sansoy, V., Fobker, M., Ceyhan, K., Toprak, S., & Assmann, G. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00025-x · Cited by 134
Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity
Chan, D. C., Watts, G. F., Barrett, P. H., Mamo, J. C., & Redgrave, T. G. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.2.278 · Cited by 117
Olin-Lewis, K., Krauss, R. M., La Belle, M., Blanche, P. J., Barrett, P. H. R., Wight, T. N., & Chait, A. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200322-jlr200 · Cited by 114
Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
Batal, R., Tremblay, M., Barrett, P. H. R., Jacques, H., Fredenrich, A., Mamer, O., Davignon, J., & Cohn, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32379-8 · Cited by 113
Apolipoprotein CIII links dyslipidemia with atherosclerosis
Kawakami, A., & Yoshida, M. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e607 · Cited by 98
Chunyu, Z., Christina, K., Katsunori, I., & Sacks, F. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.p600011-jlr200 · Cited by 95
An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
Chan, D. C., Chen, M. M., Ooi, E. M. M., & Watts, G. F. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01678.x · Cited by 85
Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk
Morton, A. M., Koch, M., Mendivil, C. O., Furtado, J. D., Tjønneland, A., Overvad, K., Wang, L., Jensen, M. K., & Sacks, F. M. (2018) · JCI Insight · doi:10.1172/jci.insight.98045 · Cited by 91
Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects
Cohn, J. S., Tremblay, M., Batal, R., Jacques, H., Veilleux, L., Rodriguez, C., Bernier, L., Mamer, O., & Davignon, J. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200055-jlr200 · Cited by 41
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
Skulas-Ray, A. C., Alaupovic, P., Kris-Etherton, P. M., & West, S. G. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.12.001 · Cited by 30
Okoro, E. U., Zhao, Y., Guo, Z., Zhou, L., Lin, X., & Yang, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044430 · Cited by 25
Nakou, E. S., Filippatos, T. D., Agouridis, A. P., Kostara, C., Bairaktari, E. T., & Elisaf, M. S. (2010) · Lipids · doi:10.1007/s11745-010-3409-0 · Cited by 23
(2004) · doi:10.1016/j.bbalip.2004.03.004 · Cited by 17
Metadata
- Authors
- Clavey, V., Lestavel-Delattre, S., Copin, C., Bard, J. M., & Fruchart, J. C.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1995-07
- Volume
- 15
- Issue
- 7
- Pages
- 963-971
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W1997090264
- Cited by
- 178
- References
- 2
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.